MedTrace Logo

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

NCT00210314 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2015-03-30

No results posted yet for this study

Summary

Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma

Conditions

  • Lymphoma, B Cell

Interventions

DRUG

high dose methotrexate

DRUG

high dose cytarabine

RADIATION

radiotherapy

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Andres JM Ferreri, MD · Radiochemotherapy. San Raffaele Hospital. Milan

  • Michele Reni, MD · Radiochemotherapy. San Raffaele Hospital. Milan

  • Emanuele Zucca, MD · International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland (IOSI)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2007-09-30
Completion
2007-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210314 on ClinicalTrials.gov